

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6505538

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JEFFREY ALAN HUBBELL	06/30/2016
DAVID SCOTT WILSON	06/29/2016
RECEIVING PARTY DATA	
Name:	ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL)
Street Address:	EPFL INNOVATION PARK J
City:	LAUSANNE
State/Country:	SWITZERLAND
Postal Code:	CH-1015
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16028209
CORRESPONDENCE DATA	
Fax Number:	(949)760-9502
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	949-760-0404
Email:	efiling@knobbe.com
Correspondent Name:	KNOBBE, MARTENS, OLSON & BEAR, LLP
Address Line 1:	2040 MAIN STREET
Address Line 2:	14TH FLOOR
Address Line 4:	IRVINE, CALIFORNIA 92614
ATTORNEY DOCKET NUMBER:	ANOK.002P2C1
NAME OF SUBMITTER:	MARK METZKE
SIGNATURE:	/Mark Metzke/
DATE SIGNED:	01/20/2021
Total Attachments: 4	
source=2018-06-25 (executed) Combined Declaration and Assignment - ANOK.002P2#page1.tif	
source=2018-06-25 (executed) Combined Declaration and Assignment - ANOK.002P2#page2.tif	
source=2018-06-25 (executed) Combined Declaration and Assignment - ANOK.002P2#page3.tif	
source=2018-06-25 (executed) Combined Declaration and Assignment - ANOK.002P2#page4.tif	

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))*Application Data Sheet filed previously or concurrently*

Docket No.: ANOK.002P2

Page 1 of 4

Title: GLYCOTARGETING THERAPEUTICS

Inventors: Jeffrey Alan Hubbell, David Scott Wilson

Declaration

This Declaration is directed to the application identified above that:

Was filed **June 17, 2016** as U.S. or International Application No. **15/185564** and incorporating any amendments made thereto prior to the signature date of this Declaration.

As a named inventor, I declare that:

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

I have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

Assignment from Inventors

WHEREAS, **above-identified inventors** (individuals, hereinafter collectively referred to as "ASSIGNOR") invented certain new and useful improvements, technology, inventions, developments, ideas, ornamental designs, or discoveries, and hereby assign or are under an obligation to assign to the below identified Assignee the above-titled application (collectively hereinafter referred to as the "Work") for which an application for Letters Patent in the United States (identified above) has been prepared for filing with the United States Patent and Trademark Office (hereinafter the "Application").

AND WHEREAS, **École Polytechnique Fédérale de Lausanne (EPFL)**, with its principal offices at EPFL Innovation Park J, CH-1015, Lausanne, Switzerland (hereinafter the "ASSIGNEE"), desires to acquire the entire right, title, and interest in and to the Application and the Work.

NOW, THEREFORE, for good and valuable consideration of which receipt is hereby acknowledged, ASSIGNOR hereby acknowledges that ASSIGNOR has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over, unto said ASSIGNEE, its successors, legal representatives and assigns, the entire right, title, and interest throughout the world in the Application and the Work, including all Patent Properties filed or issued upon the Application and the Work; where "Patent Properties" include, but are not limited to:

all provisional applications relating thereto (including but not limited to U.S. Provisional Application No(s). **61/642,942**, filed **February 21, 2014**);

all nonprovisional applications claiming priority to aforementioned provisional(s) and/or the present Application, including, all divisions, continuations, continuations-in-part, and reissues, and all Letters Patent of the United States which may be granted thereon and all reissues and extensions thereof (including but not limited to U.S. Application Nos. 14/627, 297 and 14/859,292, filed February 20, 2015 and September 19, 2015, respectively); and

all rights of priority under International Conventions and any related Letters Patent which may hereafter be granted or filed in any country or countries foreign to the United States, all extensions, renewals and reissues thereof.

PATENT**REEL: 054969 FRAME: 0545**

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))*Application Data Sheet filed previously or concurrently*

Docket No.: ANOK.002P2

Page 2 of 4

Title: GLYCOTARGETING THERAPEUTICS

Inventors: Jeffrey Alan Hubbell, David Scott Wilson

ASSIGNOR hereby acknowledges the ASSIGNEE as the Applicant for all aforementioned Patent Properties, and authorizes and requests the Commissioner of Patents of the United States, and any Official of any country or countries foreign to the United States, whose duty it is to issue patents on applications as aforesaid, to issue all related Letters Patent to the ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND ASSIGNOR DOES HEREBY sell, assign, transfer, and convey to ASSIGNEE, its successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to ASSIGNEE, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of said Letters Patent before or after issuance.

AND ASSIGNOR DOES HEREBY covenant and agree that ASSIGNOR will communicate to said ASSIGNEE, its successors, legal representatives and assigns, any facts known to ASSIGNOR respecting the Work, and testify in any legal proceeding, assist in the preparation of any other Patent Property relating to the Application and the Work or any improvements made thereto, sign/execute all lawful papers, authorize the filing of and execute and make all rightful oaths and/or declarations in connection with the Application and the Work including any improvements made thereto, any patent applications filed therefrom, and any continuing application filed from any of the aforementioned applications, and generally do everything possible to aid the ASSIGNEE, its successors, legal representatives and assigns, to obtain and enforce proper patent protection for the Work in all countries.

PATENT**REEL: 054969 FRAME: 0546**

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))

Application Data Sheet filed previously or concurrently

Docket No.: ANOK.002P2


Page 3 of 4

Title: GLYCOTARGETING THERAPEUTICS

Inventors: Jeffrey Alan Hubbell, David Scott Wilson

Legal Name of inventor: Jeffrey Alan Hubbell


IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 30th day of June, 2016.


Signature: 

Signature before a Notary is desirable but not required. When signed in presence of a Notary, please attach the appropriate notarial documentation.

STATE OF ILLINOIS
COUNTY OF COOK

Signed before me this 30th day
of June, 2016
by Jeffrey A. Hubbell


Notary Public



COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))

Application Data Sheet filed previously or concurrently

Docket No.: ANOK.002P2


Page 4 of 4

Title: GLYCOTARGETING THERAPEUTICS

Inventors: Jeffrey Alan Hubbell, David Scott Wilson

Legal Name of inventor: David Scott Wilson


Signature:



Date:

29.06.16

Witnessed by:



Witness Name (printed):

SHAN YU

23643186